Nuvation BIO Inc
NUVBNASDAQStock · Data from SEC EDGAR 13F · Held by 6 of 87 tracked investors
Nuvation BIO Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth95
- Profitability5
- Quality20
- Debt100
- Stability48
- ✓It has more cash than debt.
- ✓The analysts' average target is 186% above the price.
- !The company is loss-making: net profit is negative.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 9.3×
- EV/EBITDA
- -10.0×
Is the company growing?
–Too few years to compare. Last year 555.6%.
Does it make money?
Loss-making- Cost of sales 15
- Research 183.0
Chart NUVB
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
6SD Stanley Druckenmiller Duquesne Family Office | 0.49% |
DA David Abrams Abrams Capital Management | 0.13% |
JS Jim Simons Renaissance Technologies | 0.01% |
JG Joel Greenblatt Gotham Asset Management | 0% |
DE David Einhorn Greenlight Capital | 0% |
CA Cliff Asness AQR Capital Management | 0% |
Frequently asked questions
How much is Nuvation BIO Inc (NUVB) stock?
Nuvation BIO Inc shares trade at $4.55, +0.89% over the last trading day. The price is delayed.
What is the market cap of Nuvation BIO Inc?
The market cap of Nuvation BIO Inc is about $1.6B.
Which big investors hold Nuvation BIO Inc?
According to the latest 13F filings, 6 of 87 tracked investors hold Nuvation BIO Inc, for example Stanley Druckenmiller, David Abrams, Jim Simons.
When will Nuvation BIO Inc report its next results?
The next earnings report of Nuvation BIO Inc is expected on 4 Nov 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.